ArticleJournal of the American Geriatrics Society2016
Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.
Article in Journal of the American Geriatrics Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Pooled it
- Brexpiprazole for agitation in clinically relevant patient subgroups: aCurrent medical research and opinion · 2025Trial
- Current Psychotropic Medication Use and Contributing Factors Among Nursing Home Residents With Cognitive Impairment.Clinical nursing research · 2021Trial
- Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2019Trial
- Impact of national cognitive screening on dementia care and hospitalization in South Korea.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials.Systematic reviews · 2025Article
- The National Dementia Workforce Study: Overview.Journal of the American Geriatrics Society · 2025Article
- The National Dementia Workforce Study: Methods for Surveying Community Clinicians Who Provide Care to People With Dementia.Journal of the American Geriatrics Society · 2025Article
- Differentiation Between Early and Severe Stages of Dementia in Claims Data Based on Diagnosis, Prescription, and Utilization Patterns.Neurology and therapy · 2025Article
- Patient management pathways in dementia - Resource utilisation, diagnosis and drug treatment in the Stockholm region, Sweden.The journal of prevention of Alzheimer's disease · 2025Observational
- Regional variations in healthcare in people living with dementia in Germany: protocol for a mixed-methods study.BMJ open · 2025Article
- Inequalities in the Quality and Safety of Post-Diagnostic Primary Care for People With Dementia: A Scoping Review.International journal of geriatric psychiatry · 2024Article
- Geographic Variation of Antidementia and Antipsychotic Medication Use Among US Nursing Home Residents With Dementia.Medical care · 2024Article
- Antidementia Medication Use in Nursing Home Residents.Journal of geriatric psychiatry and neurology · 2024Article
- Effects of Medicare Part D medication therapy management on racial/ethnic disparities in adherence to antidementia medications among patients with Alzheimer's disease and related dementias: An observational study.Exploratory research in clinical and social pharmacy · 2024Article
- Non-adherence to antidementia medications and associated factors: a study of Spanish population-based registry data.Frontiers in pharmacology · 2024Article
- Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.Alzheimer's research & therapy · 2023Article
- Accountable care organizations and use of surgery among patients with Alzheimer disease and related dementias.The American journal of managed care · 2023Article
- State Variation in Antipsychotic Use Among Assisted Living Residents With Dementia.Journal of the American Medical Directors Association · 2023Observational
- Alzheimer's disease medication use and adherence patterns by race and ethnicity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
objectivesTo evaluate frequency of use of two anti-dementia drug classes approved for treatment of symptoms, whether populations most likely to benefit are treated, and correlates of treatment initiation.
designNationally representative cohort study.
settingFee-for-service Medicare.
participantsElderly adults with dementia enrolled in Medicare Parts A, B, and D in 2009 (N = 433,559) and a subset with incident dementia (n = 185,449). MEASUREMENTS: Main outcome was any prescription fill for antidementia drugs (cholinesterase inhibitors (ChEIs) or memantine) within 1 year.
resultsTreatment with antidementia drugs occurred in 55.8% of all participants with dementia and 49.3% of those with incident dementia. There was no difference between ChEIs and memantine use according to dementia severity (measured as death within first year or living in residential care vs in a community setting) even though memantine is not indicated in mild disease. In incident cases, initiation of treatment was lower in residential care (relative risk (RR) = 0.82, 95% confidence interval (CI) = 0.81-0.83) and with more comorbidities (RR = 0.96, 95% CI = 0.96-0.96). Sixty percent of participants were managed in primary care alone. Seeing a neurologist (RR = 1.07, 95% CI = 1.06-1.09) or psychiatrist (RR = 1.17, 95% CI = 1.16-1.19) was associated with higher likelihood of treatment than seeing a primary care provider alone, and seeing geriatrician was associated with with lower likelihood (RR = 0.96, 95% CI = 0.93-0.99). Across the United States, the proportion of newly diagnosed individuals started on antidementia treatment varied from 32% to 66% across hospital referral regions.
conclusionAntidementia drugs are used less often in people with late disease, but there is no differentiation in medication choice. Although primary care providers most often prescribe antidementia medication without specialty support, differences in practice between specialties are evident.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.